{"schema_version":"1.0","type":"article","title":"B 肝新藥在日本獲准，新藥組約兩成受試者達「功能性治癒」","url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.md","lang":"zh-Hant","date":"2026-09-27","publish_at":"2026-09-27T08:00:00+08:00","updated_at":"2026-09-27","category":"商業分析系列","topic":"商業分析系列","tags":["B 型肝炎","GSK","Hibsago","有限療程","普生"],"summary":"2026 年 8 月 24 日，GSK 宣布 Hibsago（bepirovirsen）在日本獲准，用於符合條件的成人慢性 B 肝患者。支持核准的第三期結果已於 5 月發表；這次進展，是有限療程從試驗證據走向特定人群的治療選擇。","key_points":[],"facts":[],"sections":["【01｜先找到適合的人，才能談有限療程的價值】","【02｜24、48、72 週，回答的是三個不同問題】","【03｜停藥後的結果，讓改善幅度有了清楚分母】","【04｜有限療程改變支付問題，也重新安排照護工作】","【05｜下一代治療設計，要擴大的是持續控制的機會】","【06｜台灣可看的真能力，是肝炎檢驗與治療監測】","【結語｜新核准打開選擇，長期價值要沿治療歷程驗證】","【資料來源】"],"references":[],"images":[{"alt":"肝細胞中的 RNA 與病毒蛋白生成路徑受到反義寡核苷酸介入，旁列 NA 背景治療；細胞核中的病毒儲存形式仍保留，沒有病毒根除或治癒勾選。","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care/01_RNA%E8%88%87%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B_ZH_v2.png"},{"alt":"兩條治療帶共用0到72週時間軸，試驗藥在24週結束，NA在48週經資格判定後才可能停止，72週以HBsAg和HBV DNA檢驗確認結果。","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care/02_%E6%B2%BB%E7%99%82%E8%88%87%E8%BF%BD%E8%B9%A4%E6%99%82%E9%96%93%E8%BB%B8_ZH_v1.png"},{"alt":"兩個同量尺柱狀面板，分別列B-Well1約20%對0%、B-Well2約19%對0%，每柱標示達標人數與原分母，旁註72週端點和至少24週停藥觀察。","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care/03_%E5%85%A9%E8%A9%A6%E9%A9%97%E5%81%9C%E8%97%A5%E5%BE%8C%E7%AB%AF%E9%BB%9E_ZH_v1.png"},{"alt":"檢驗與醫師評估、用藥日曆與支付文件、回診採血追蹤三個等大場景相連，表示有限療程需要完整照護銜接，沒有價格、保證停藥或營收成長。","url":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care/04_%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B%E5%AE%8C%E6%95%B4%E7%85%A7%E8%AD%B7_ZH_v2.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hibsago-finite-hbv-care/01_RNA%E8%88%87%E6%9C%89%E9%99%90%E7%99%82%E7%A8%8B_ZH_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-27）。B 肝新藥在日本獲准，新藥組約兩成受試者達「功能性治癒」。https://drugnews.com.tw/articles/2026-09-27-hibsago-finite-hbv-care.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-27-hibsago-finite-hbv-care-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}